

General information about company		
Scrip code	544319	
NSE Symbol	SENORES	
MSEI Symbol	NA	
ISIN	INE0RB801010	
Name of the entity	SENORES PHARMACEUTICALS LIMITED	
Date of start of financial year	01-04-2024	
Date of end of financial year	31-03-2025	
Reporting Quarter Type	Yearly	
Date of Quarter Ending	31-03-2025	
Type of company	Equity	
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes	
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes	
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	Yes	
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	Yes	
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	Yes	
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	Yes	
Risk management committee	Applicable	
Market Capitalisation as per immediate previous Financial Year	Top 1000 listed entities	
Is SCORE ID Available ?	Yes	
SCORE Registration ID	coms02068	
Reason For No SCORE ID		
Type of Submission	Original	
Remarks (website dissemination)		
Remarks for Exchange (not for Website Dissemination)	The Company got listed on December 30, 2024. Based on Market Capitalisation list of Exchanges as on December 31,2024, the Company falls under Top 1000 Listed entities.	

Annexure I								
Annexure I to be submitted by listed entity on quarterly basis								
I. Composition of Board of Directors								
Disclosure of notes on composition of board of directors explanatory								
Whether the listed entity has a Regular Chairperson							Yes	
Whether Chairperson is related to MD or CEO							No	
Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth
1	Mr	Sanjay Shaileshbhai Majmudar	*****	00091305	Non-Executive - Non Independent Director	Chairperson		21-03-1963
2	Mr	Swapnil Jatinbhai Shah	*****	05259821	Executive Director	Not Applicable	MD	01-07-1985
3	Mr	Hemanshu Nitinchandra Pandya	*****	10383995	Non-Executive - Non Independent Director	Not Applicable		12-10-1971
4	Mr	Jitendra Babulal Sanghvi	*****	00271995	Non-Executive - Non Independent Director	Not Applicable		23-08-1979
5	Mr	Chetan Bipinchandra Shah	*****	10381971	Executive Director	Not Applicable		20-04-1966
6	Mr	Deval Rajnikant Shah	*****	00332722	Executive Director	Not Applicable		06-09-1963
7	Mr	Ashokbhai Vijaysinh Barot	*****	01192300	Non-Executive - Non Independent Director	Not Applicable		04-09-1966
8	Mr	Shah Arpit Deepakkumar	*****	07214641	Non-Executive - Non Independent Director	Not Applicable		11-09-1987
9	Mr	Naresh Bansilal Shah	*****	10384306	Non-Executive - Independent Director	Not Applicable		18-03-1947
10	Ms	Manjuladevi Pratul Shroff	*****	00297159	Non-Executive - Independent Director	Not Applicable		27-02-1964
11	Mr	Kalpiti Rajesh Gandhi	*****	02843308	Non-Executive - Independent Director	Not Applicable		03-02-1985
12	Mr	Udayan Dileep Choksi	*****	02222020	Non-Executive - Independent Director	Not Applicable		14-01-1976

I. Composition of Board of Directors					
Disqualification of Directors under section 164 of the Companies Act, 2013					
Sr	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status
1	No				Active
2	No				Active
3	No				Active
4	No				Active
5	No				Active
6	No				Active
7	No				Active
8	No				Active
9	No				Active
10	No				Active
11	No				Active
12	No				Active

I. Composition of Board of Directors													
Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & reg. 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	NA		10-02-2024	10-02-2024			4	1	2	2			
2	NA		15-10-2021	15-10-2021			2	0	4	0			
3	NA		10-11-2023	10-11-2023			1	0	0	0		Textual Information(1)	
4	NA		23-11-2021	23-11-2021			1	0	0	0			
5	NA		10-11-2023	10-11-2023			1	0	0	0			
6	NA		01-01-2020	01-05-2024			1	0	0	0			
7	NA		15-05-2018	15-05-2018			1	0	0	0			
8	NA		10-11-2023	10-11-2023			2	0	2	0			
9	Yes	19-02-2024	30-01-2024	30-01-2024		14.01	1	1	1	0			
10	NA		30-01-2024	30-01-2024		14.01	2	2	3	0			
11	NA		30-01-2024	30-01-2024		14.01	2	1	2	1			
12	NA		08-03-2024	08-03-2024		12.23	2	2	3	0			

Text Block	
Textual Information(1)	Mr. Hemanshu Nitinchandra Pandya is NRI, hence not having PAN.

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	02843308	Kalpiti Rajesh Gandhi	Non-Executive - Independent Director	Chairperson	09-04-2024		
2	02222020	Udayan Dileep Choksi	Non-Executive - Independent Director	Member	09-04-2024		
3	10384306	Naresh Bansilal Shah	Non-Executive - Independent Director	Member	09-04-2024		
4	05259821	Swapnil Jatinbhai Shah	Executive Director	Member	09-04-2024		

Nomination and remuneration committee							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	02222020	Udayan Dileep Choksi	Non-Executive - Independent Director	Chairperson	09-04-2024		
2	02843308	Kalpiti Rajesh Gandhi	Non-Executive - Independent Director	Member	09-04-2024		
3	00091305	Sanjay Shaileshbhai Majmudar	Non-Executive - Non Independent Director	Member	09-04-2024		

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00091305	Sanjay Shaileshbhai Majmudar	Non-Executive - Non Independent Director	Chairperson	09-04-2024		
2	02843308	Kalpiti Rajesh Gandhi	Non-Executive - Independent Director	Member	09-04-2024		
3	00297159	Manjuladevi Pratul Shroff	Non-Executive - Independent Director	Member	09-04-2024		
4	05259821	Swapnil Jatinbhai Shah	Executive Director	Member	09-04-2024		

Risk Management Committee							
Whether the Risk Management Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	10381971	Chetan Bipinchandra Shah	Executive Director	Chairperson	09-04-2024		
2	00091305	Sanjay Shaileshbhai Majmudar	Non-Executive - Non Independent Director	Member	09-04-2024		
3	05259821	Swapnil Jatinbhai Shah	Executive Director	Member	09-04-2024		
4	02222020	Udayan Dileep Choksi	Non-Executive - Independent Director	Member	09-04-2024		

Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00297159	Manjuladevi Pratul Shroff	Non-Executive - Independent Director	Chairperson	12-06-2024		
2	05259821	Swapnil Jatinbhai Shah	Executive Director	Member	12-06-2024		
3	01192300	Ashokbhai Vijaysinh Barot	Non-Executive - Non Independent Director	Member	12-06-2024		

Other Committee						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

Annexure 1								
Annexure 1								
III. Meeting of Board of Directors								
Disclosure of notes on meeting of board of directors explanatory								
Sr. No.	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
1	16-11-2024				Yes	12	11	4
2	06-12-2024		19		Yes	12	10	3
3	15-12-2024		8		Yes	12	5	2
4	24-12-2024		8		Yes	12	5	2
5	28-12-2024		3		Yes	12	5	2
6		23-01-2025	25		Yes	12	10	3

Annexure 1										
IV. Meeting of Committees										
Disclosure of notes on meeting of committees explanatory										
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Audit Committee	16-11-2024				Yes	4	3	3	0
2	Audit Committee	06-12-2024	19			Yes	4	4	3	0
3	Audit Committee	15-12-2024	8			Yes	4	3	2	0
4	Audit Committee	24-12-2024	8			Yes	4	3	2	0
5	Audit Committee	23-01-2025	29			Yes	4	4	3	0
6	Nomination and remuneration committee	16-11-2024				Yes	3	3	3	0

Annexure 1										
IV. Meeting of Committees										
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
7	Stakeholders Relationship Committee	23-01-2025	67			Yes	4	3	1	0

Annexure 1		
V. Affirmations		
Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

Annexure 1		
Sr	Subject	Compliance status
1	Name of signatory	VINAY KUMAR MISHRA
2	Designation	Company Secretary and Compliance Officer

Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)				
I. Disclosure on website in terms of LODR Regulation				
Sr				
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
	As per regulation 46(2) of the LODR:			
1.1	Details of business	Yes		https://senorespharma.com/about-us/
1.2	Memorandum of Association and Articles of Association	Yes		https://senorespharma.com/moa-aoa/
1.3	Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		https://senorespharma.com/leadership/
2	Terms and conditions of appointment of independent directors	Yes		https://senorespharma.com/leadership/
3	Composition of various committees of board of directors	Yes		https://senorespharma.com/committees/
4	Code of conduct of board of directors and senior management personnel	Yes		https://senorespharma.com/wp-content/uploads/2024/07/Code-of-Conduct-for-Directors-and-Senior-Management-Personnel.pdf
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		https://senorespharma.com/wp-content/uploads/2024/07/Whistle-Blower-Policy.pdf
6	Criteria of making payments to non-executive directors	Yes		https://senorespharma.com/wp-content/uploads/2024/12/Criteria-for-making-payments-to-NEDs.pdf
7	Policy on dealing with related party transactions	Yes		https://senorespharma.com/wp-content/uploads/2024/07/Related-Party-Transactions-policy.pdf
8	Policy for determining 'material' subsidiaries	Yes		https://senorespharma.com/wp-content/uploads/2024/07/Policy-on-Material-Subsidiaries.pdf
9	Details of familiarization programmes imparted to independent directors	Yes		https://senorespharma.com/wp-content/uploads/2024/07/Policy-on-Familiarization-Program-for-Independent-Directors.pdf
10	Email address for grievance redressal and other relevant details	Yes		https://senorespharma.com/investor-grievance/
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		https://senorespharma.com/investor-grievance/
12	Financial results	Yes		https://senorespharma.com/financials/
13	Shareholding pattern	Yes		https://senorespharma.com/shareholding/
14	Details of agreements entered into with the media companies and/or their associates	NA		

Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)				
I. Disclosure on website in terms of LODR Regulation				
Sr				
	As per regulation 46(2) of the LODR:			
15.1	(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	Yes		https://senorespharma.com/investor-meet/
15.2	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means	Yes		https://senorespharma.com/investor-meet/
16	New name and the old name of the listed entity	NA		
17	Advertisements as per regulation 47 (1)	Yes		https://senorespharma.com/wp-content/uploads/2025/01/Intimation-for-Newspaper-Publication-24.01.2025.pdf
18	Credit rating or revision in credit rating obtained	NA		
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes		https://senorespharma.com/financials/
20	Secretarial Compliance Report	No	The Company got listed on December 30, 2024. Hence, the Secretarial Compliance Report for Financial Year 2024-25 will be uploaded in due course.	
21	Materiality Policy as per Regulation 30 (4)	Yes		https://senorespharma.com/wp-content/uploads/2024/07/Materiality-Policy.pdf
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes		https://senorespharma.com/investor-grievance/
23	Disclosures under regulation 30(8)	Yes		https://senorespharma.com/announcements/
24	Statements of deviation(s) or variations(s) as specified in regulation 32	Yes		https://senorespharma.com/announcements/
25	Dividend Distribution policy as per Regulation 43A(1)	Yes		https://senorespharma.com/wp-content/uploads/2024/07/Dividend-Distribution-Policy.pdf
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes		https://senorespharma.com/reports/
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	NA		
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes		https://senorespharma.com/reg-46-of-sebi-lodr-regulations/
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes		https://senorespharma.com/reg-46-of-sebi-lodr-regulations/

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of ‘independence’ and/or ‘eligibility’	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
26	Meeting of Risk Management Committee	21(3A)	Yes	
27	Quorum of Risk Management Committee meeting	21(3B)	Yes	
28	Gap between the meetings of the Risk Management Committee	21(3C)	Yes	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4), (5) & (6)	Yes	
36	Alternate Director to Independent Director	25(1)	NA	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	Yes	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	Yes	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	Yes	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	Yes	
	Any other information to be provided - Add Notes			

Annexure II		
1	Name of signatory	VINAY KUMAR MISHRA
2	Designation	Company Secretary and Compliance Officer

Annexure II		
III. Affirmations		
Sr	Particulars	Compliance status (Yes/No/NA)
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes
	Any other information to be provided	

Annexure II		
1	Name of signatory	VINAY KUMAR MISHRA
2	Designation	Company Secretary and Compliance Officer

Additional Half yearly Disclosure DISCLOSURE OF LOANS / GUARANTEES / COMFORT LETTERS / SECURITIES ETC. (applicable only for half-yearly filings)			
Any Other Information for Disclosure of Loans / Guarantees / Comfort Letters / Securities Etc.			Textual Information(1)
I. Disclosure of Loans/ guarantees/comfort letters /securities etc. Refer note below			
(A)Any loan or any other form of debt advanced by the listed entity directly or indirectly to			
Entity	Aggregate amount advanced during six months	Balance outstanding at the end of six months	
Promoter or any other entity controlled by them	0	0	
Promoter Group or any other entity controlled by them	0	0	
Directors (including relatives) or any other entity controlled by them	0	0	
KMPs or any other entity controlled by them	0	0	
(B) Any guarantee / comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed By			
Entity	Type (guarantee, comfort letter etc.)	Aggregate amount of issuance during six months	Balance outstanding at the end of six months(taking into account any invocation)
Promoter or any other entity controlled by them	Not Applicable	0	0
Promoter Group or any other entity controlled by them	Not Applicable	0	0
Directors (including relatives) or any other entity controlled by them	Not Applicable	0	0
KMPs or any other entity controlled by them	Not Applicable	0	0
(C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by			
Entity	Type of security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	Not Applicable	0	0
Promoter Group or any other entity controlled by them	Not Applicable	0	0
Directors (including relatives) or any other entity controlled by them	Not Applicable	0	0
KMPs or any other entity controlled by them	Not Applicable	0	0
(D) Additional Information			Textual Information(2)
II. Affirmations			
Affirmations		Compliance Status	Company Remarks
All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.		No	Textual Information(3)
Name	DEVAL RAJNIKANT SHAH		
Designation	CFO		
Place	AHMEDABAD		
Date	25-04-2025		

Text Block	
Textual Information(3)	During the half year, no loans, guarantees, comfort letters or securities in connection with any loans is given by the company.

Details of Cyber security incidence		
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter		No
Number of cyber security incidence or breaches or loss of data event occurred during the quarter		
Sr.	Date of the event	Brief details of the event

Signatory Details	
Name of signatory	VINAY KUMAR MISHRA
Designation of person	Company Secretary and Compliance Officer
Place	AHMEDABAD
Date	25-04-2025

Investor Grievance Details	
No. of investor complaints pending at the beginning of Quarter	70
No. of investor complaints received during the Quarter	159
No. of investor complaints disposed off during the Quarter	229
No. of investor complaints those remaining unresolved at the end of the Quarter	0

Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies- The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III are given below:					
Any Other Information for Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies					Textual Information(1)
Sr. No.	Name of the unlisted company in which shares or voting rights have been acquired	Date of acquisition	Aggregate holding (% shares or voting rights) as at the end of the previous quarter	% shares or voting rights acquired during the quarter	Aggregate holding (% shares or voting rights) as at the end of the quarter
1	SENORES PHARMACEUTICALS INC.(WHOLLY OWNED SUBSIDIARY)	20-01-2025	100	0	100
2	HAVIX GROUP INC. D/B/A AAVIS PHARMACEUTICALS	05-03-2025	49.91	1.32	51.23
3	HAVIX GROUP INC. D/B/A AAVIS PHARMACEUTICALS	24-06-2025	51.23	3.73	54.96
4	SENORES PHARMACEUTICALS INC.(WHOLLY OWNED SUBSIDIARY)	20-03-2025	100	0	100

Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies- The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III are given below: Text Block	
Textual Information(1)	In respect of Row No 1 and 4 -Senores Pharmaceuticals Inc. is a wholly owned subsidiary of the Company. So, there is no change in the pre and post shareholding of the Company. In respect of Row No 3- Indicative time period for completion of the acquisition of 8454 equity shares was initially 45 days from the date of execution of Share Purchase Agreement i.e on or before April 25,2025. Out of said 8454 equity shares the Company has acquired 7914 equity shares and acquisition of 540 equity shares is under process due to requirements of certain RBI approvals, in view of the same the time period for acquisition of remianing 540 equity shares has been further extended by 60 days. In respect of Row No 2 and 3 - Post acquisition the direct shareholding of the Company in Havix will increase from 51.23% to 54.96% and the aggregate shareholding of the Company (along with the shareholding of its wholly owned subsidiary Senores Pharmaceuticals, Inc.) in Havix will increase from 66.58% to 70.31%.

Disclosure of Imposition of Fine or Penalty The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:					
Any Other Information for Disclosure of Imposition of Fine or Penalty					Textual Information(1)
Sr. No.	Name of the authority	Nature and details of the action(s) taken or order(s) passed	Date of receipt of direction or order, including any ad interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
1	Central Ground Water Authority	Imposed the penalty of Rs 2,10,000 on account of Non installation/Faulty Digital water flow meter with telemetry system, Revival charges.	26-01-2025	Non installation/faulty Digital water Flow meter with telemetry system - Revival charges	There is no material impact on financials, operations or other activities of the Company.

Disclosure of Imposition of Fine or Penalty The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below: Text Block	
Textual Information(1)	Penalty of Rs 2,10,000 pertains to one of our Material Subsidiaries- Ratnatris Pharmaceuticals Private Limited.

Disclosure of Updates to Ongoing Tax Litigations or Disputes The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:				
Any Other Information for Disclosure of Updates to Ongoing Tax Litigations or Disputes				Textual Information(1)
Sr. No.	Name of the opposing party	Date of initiation of the litigation / dispute	Status of the litigation / dispute as per last disclosure	Current status of the litigation / dispute
1	Income Tax Department	28-09-2019	Demand raised as per regular assessment for AY 18-19. Writ petition filed with High Court against the assessment order passed. High court has issued stay order.	No change in the status
2	Income Tax Department	27-06-2022	Assessment Completed on 30.12.2022 for AY 2021-22 and appeal filed with CIT(A) which is pending for adjudication.	No change in the status
3	Office of the Commissioner Central GST, Audit, Ahmedabad	26-01-2024	Intimation of tax ascertained as being payable u/s 74(5) of CGST Act, 2017 on revenue para 6, 7 and 8 of FAR No. GST -46/2024-25 dated 31.05.24	No change in the status

Disclosure of Updates to Ongoing Tax Litigations or Disputes The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below: Text Block	
Textual Information(1)	Sr.No.1 and 2, pertains to one of our Material Subsidiaries- Ratnatris Pharmaceuticals Private Limited.

